Busulfan

證據等級: L5

預測適應症: 10 個

Busulfan: From Chronic Myeloid Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Busulfan is a classic bifunctional alkylating agent, historically developed for chronic myeloid leukemia and now used mainly as a myeloablative conditioning agent before allogeneic hematopoietic stem cell transplantation (allo-HSCT). The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS), with 50 clinical trials and 20 publications currently supporting this direction, including completed Phase 3 randomized trials.

Quick Overview

Item	Content
Original Indication	Chronic myeloid leukemia / myeloablative conditioning agent (based on general pharmacological knowledge — not captured in the current Finland regulatory dataset, which contains no license records)
Predicted New Indication	Myelodysplastic Syndrome
TxGNN Prediction Score	99.62%
Evidence Level	L1
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the evidence pack (MOA field marked as a data gap). Based on well-established pharmacology, busulfan is a bifunctional alkylating agent that cross-links DNA, producing profound, dose-dependent myeloablation. Its established modern clinical role is as a component of myeloablative/reduced-intensity conditioning regimens (typically combined with fludarabine or cyclophosphamide) given immediately before allo-HSCT.

MDS is a clonal hematopoietic stem cell disorder for which allo-HSCT remains the only potentially curative treatment in higher-risk disease. To perform allo-HSCT, the recipient's abnormal marrow must first be ablated to allow donor stem cells to engraft — this is exactly the role busulfan-based conditioning already plays in routine clinical practice for MDS. As the repurposing rationale notes, this is not a novel biological hypothesis so much as a confirmation of an already-standard clinical pathway: busulfan-based conditioning (Bu/Flu, Bu/Cy, timed-sequential busulfan, etc.) is widely used pre-transplant for MDS patients, which explains both the very high TxGNN score and the unusually deep clinical trial/literature base for this pairing.

The mechanistic link is therefore strong and directly supported by decades of transplant literature, rather than purely computational inference — multiple Phase 3 randomized trials directly compare busulfan-based conditioning regimens in MDS/AML populations undergoing allo-HSCT.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00416598	Phase 2	Completed	546	Maintenance decitabine after busulfan-containing induction/intensification in AML/MDS; large completed study, grade A relevance
NCT02250937	Phase 2	Active, not recruiting	116	Venetoclax + timed-sequential busulfan/cladribine/fludarabine conditioning directly in AML and MDS patients
NCT06477549	Phase 2	Recruiting	220	Randomized comparison of bendamustine vs. ruxolitinib added to fludarabine/busulfan conditioning in haploidentical HSCT
NCT02861417	Phase 2	Active, not recruiting	204	Timed-sequential busulfan plus post-transplant cyclophosphamide conditioning for blood cancers including MDS
NCT00454480	Phase 2/3	Completed	2000	Large treatment-development program for older AML/high-risk MDS patients, including busulfan-based regimens
NCT00002989	Phase 3	Unknown	207	Randomized Phase 3 trial intensifying the conditioning regimen for allo-HSCT in leukemia/MDS with high relapse risk
NCT03779854	Phase 2	Recruiting	68	Multicenter randomized trial of naïve T-cell depletion for chronic GVHD prevention post-transplant
NCT01861106	Phase 2	Recruiting	144	Allo-HSCT for GATA2 deficiency/MonoMAC syndrome, a condition that frequently progresses to MDS
NCT00186342	N/A	Completed	120	Busulfan, etoposide and cyclophosphamide conditioning for MDS/MPD patients aged 51–60
NCT01622556	Phase 2	Terminated	6	Reduced-intensity busulfan/TBI/thymoglobulin conditioning with cord blood transplant; small, terminated, limited value

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31606445	2020	RCT (Phase 3)	The Lancet Haematology	Randomized non-inferiority trial: treosulfan vs. busulfan/fludarabine conditioning in older AML/MDS patients undergoing allo-HSCT
28380315	2017	RCT (Phase 3)	J Clin Oncol	Randomized trial comparing myeloablative vs. reduced-intensity busulfan-based conditioning for AML/MDS
36702138	2023	RCT (Phase 3)	The Lancet Haematology	Open-label multicenter randomized trial: G-CSF+decitabine+busulfan/cyclophosphamide vs. busulfan/cyclophosphamide alone to reduce relapse in MDS/secondary AML
35617104	2022	Cohort	American Journal of Hematology	Final analysis: treosulfan improves outcomes vs. reduced-intensity busulfan in older AML/MDS allo-HSCT patients
33425740	2020	Systematic Review / Meta-analysis	Frontiers in Oncology	Long-term outcomes of treosulfan- vs. busulfan-based conditioning in MDS/AML before HSCT
38648898	2024	Cohort	Transplantation and Cellular Therapy	Propensity-matched retrospective comparison of treosulfan- vs. busulfan-based conditioning in MDS (n=138)
40079242	2025	Review	American Journal of Hematology	Contemporary review of allogeneic HSCT for MDS and myelofibrosis, covering conditioning strategy
38176654	2024	Retrospective cohort	Transplantation and Cellular Therapy	Long-term complications after treosulfan- vs. busulfan-based conditioning in pediatric acute leukemia/MDS
37579918	2023	Cohort	Transplantation and Cellular Therapy	Myeloablative busulfan + fludarabine with in vivo T-cell depletion shown safe and effective for AML/MDS
34489555	2021	Propensity-matched cohort	Bone Marrow Transplantation	Fludarabine/busulfan vs. busulfan/cyclophosphamide myeloablative conditioning for MDS, nationwide Japanese registry

Finland Market Information

Busulfan currently holds no marketing authorization records in the evidence pack for Finland (market status: Not marketed; 0 authorizations on file). No product-level licensing data is available for evaluation.

Cytotoxicity

Busulfan is a well-established cytotoxic alkylating agent used in high-dose myeloablative regimens; it qualifies as antineoplastic/cytotoxic based on drug class (alkylating agent) and its role in myeloablative chemotherapy.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent; myeloablative conditioning agent)
Myelosuppression Risk	High — myeloablation is the intended therapeutic effect; profound, prolonged pancytopenia is expected by design, particularly at HSCT-conditioning doses
Emetogenicity Classification	High (especially at high-dose IV conditioning regimens)
Monitoring Items	CBC with differential, hepatic function (veno-occlusive disease/sinusoidal obstruction syndrome risk), pulmonary function ("busulfan lung"/pulmonary fibrosis), seizure precautions at high dose, and therapeutic drug monitoring (busulfan plasma levels) where used for conditioning
Handling Protection	Cytotoxic drug handling precautions required (PPE, closed-system transfer devices per institutional cytotoxic handling protocols)

One identified publication (PMID 37856098) specifically evaluates busulfan's association with secondary malignancy risk, relevant to long-term safety monitoring in non-malignant or curative-intent transplant settings.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in the evidence pack (DDI query returned no results), and this is flagged as a Blocking data gap (DG001) that must be resolved before any S1 safety assessment.

Other Predicted Indications (Lower Priority)

This evidence pack also scored busulfan against 9 additional candidate indications, all ranked below MDS and mechanistically related to it as a broader hematologic-malignancy/bone-marrow-failure cluster, except two flagged as likely graph artifacts:

Rank	Indication	Evidence Level	Recommendation
2	Refractory cytopenia of childhood	L2	Research Question
3	Unclassified myelodysplastic syndrome	L3	Research Question
4	Partial deletion of chromosome 5q (5q- syndrome)	L5	Hold
5	Aregenerative anemia (aplastic anemia)	L2	Proceed with Guardrails
6	Severe congenital hypochromic anemia w/ ringed sideroblasts	L5	Hold
7	HIV infectious disease	L3	Research Question
8	Neurodevelopmental disorder (ataxic gait/absent speech)	L5	Hold — likely graph noise
9	Seborrheic keratosis	L5	Hold — likely false positive
10	Feline acquired immunodeficiency syndrome	L5	Hold — non-human species, should be excluded from evaluation

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Myelodysplastic syndrome has the strongest evidence base of all predicted indications (L1: multiple completed Phase 3 RCTs directly comparing busulfan-based conditioning regimens in this population), and busulfan-based conditioning is already an established standard of care ahead of allo-HSCT for MDS. However, busulfan is currently unmarketed in Finland and critical safety documentation (TFDA/Fimea label warnings and contraindications) is missing, so guardrails are required before proceeding.

To proceed, the following is needed:

Resolve blocking data gap DG001: obtain official Finnish/EU package insert warnings and contraindications
Resolve high-priority data gap DG002: confirm detailed mechanism of action from DrugBank or product label
Confirm whether any Finland/EU marketing authorization exists for busulfan under any brand (e.g., Busilvex) despite the "not marketed" status shown here
Establish a drug-drug interaction profile (current DDI query returned no data)
Develop a monitoring and cytotoxic-handling protocol specific to conditioning-dose use in MDS transplant candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.